LivaNova PLC
In the published model solve dated 2026-Q2, anchored at $81.90, LivaNova PLC (LIVN) is priced for today's economics sustained for ~5.2 years. boothcheck publishes no house fair value, target price, or buy/sell rating; individual model outputs and user-controlled scenarios are analytical inputs, not Boothcheck targets. The narrative was composed June 27, 2026 from SEC EDGAR filings.
• LivaNova is a medical-device maker built on two franchises, cardiopulmonary equipment used in cardiac surgery and a neuromodulation business anchored by its VNS Therapy implant for epilepsy, with a newer push into sleep apnea via the aura6000 nerve-stimulation system. • The defining risk is the price relative to demonstrated profit: at roughly 21 times company-wide operating income, the stock requires operating profit to grow about 23% a year for five years, well above the high-single-digit re
Is LIVN overvalued? See what's priced in →
282 institutional managers reported holding LIVN in 13F filings for the quarter ended 2026-03-31. 48 opened new positions that quarter. Held by BlackRock, PRIMECAP Management, FMR (Fidelity), among others. On the short side, 3.5M shares were sold short as of the 2026-06-15 count, about 6% of shares outstanding (4.6 days of typical volume to cover).
Quarterly 13F filings arrive up to 45 days after quarter end, so the picture is never current (filed through 2026-05-29). Nothing here is investment advice.
LIVN's share count grew 11.8% over the past five years. It pays no dividend.
Share counts are split-adjusted; repurchase totals are gross of share issuance. Nothing here is investment advice.
No open-market insider buys on file at LIVN over the trailing three years. Absence is a fact about the company, not a signal. 17 officers and directors are on file.
Code P open-market purchases from SEC Form 4 filings, non-derivative, excluding scheduled 10b5-1 plans. Nothing here is investment advice.
LIVN's recent reports: the day-one move, then what the following quarter actually did.
| report | day one | next quarter |
|---|---|---|
| 2023-07-27 | +7.0% | -6.0% |
| 2023-11-02 | -0.8% | +2.3% |
| 2024-03-01 | +6.9% | +16.1% |
| 2024-05-04 | +12.9% | -18.2% |
Day-one is the close-to-close move around the filing. Nothing here is investment advice.
LIVN's latest 8-K filings: 2026-06-11 (items 5.07, 9.01); 2026-05-06 (items 2.02, 9.01); 2026-02-25 (items 2.02, 9.01); 2026-01-14 (items 5.02); 2025-11-05 (items 2.02, 9.01).
Item codes are the SEC's own classification of what each report discloses. Dates link to the filing on EDGAR. Nothing here is investment advice.
Model solve date: 2026-Q2
Narrative composed: June 27, 2026
Each week boothcheck ranks the stocks whose prices are betting on the most. Read the most stretched bets archive →
boothcheck is also on Android. Get the app on Google Play →
For informational and research purposes only. Not investment advice. Not a recommendation to buy, sell, or hold any security. boothcheck is not a registered investment adviser. Past performance does not guarantee future results.